

TO: Jeremy Sarnat, MD
Principal Investigator

CC: Greenwald Robert Envir & occup Health
Kewada Priya Envir & occup Health
Greenwald Robert Envir & occup Health
Wongtrakool Cherry MedPulm

DATE: May 5, 2010

RE: **Notification of Continuing Review Full Board Approval**
CR2_IRB00018855
IRB00018855
The Atlanta Commuters Exposure Study

This is your notification that your above referenced Continuing Review was reviewed and **APPROVED** under the Full Board review process by Committee B on April 27, 2010. This approval is valid from **April 27, 2010** to **April 26, 2011**. Thereafter, continued approval is contingent upon the submission of a renewal form that must be reviewed and approved by the IRB prior to the expiration date of this study.

- The study is now considered minimal risk and can be expedited in the future.
- A Partial HIPAA Wavier was granted.
- Protocol Version 4 was approved
- Consent Version Date: June 17, 2010 was approved.
- HIPAA Version Date: March 5, 2009 was approved.

Any reportable events (serious adverse events, breaches of confidentiality, protocol deviation or protocol violations) or issues resulting from this study should be reported immediately to the IRB and to the sponsoring agency (if any). Any amendments (changes to any portion of this research study including but not limited to protocol or informed consent changes) must have IRB approval before being implemented.

Please include the IRB ID, the name of the Principal Investigator and the Study Title in all future inquiries.

Sincerely,

Carla C. Belk, PhD
Sr. Research Protocol Analyst

This letter has been digitally signed

Emory University
1599 Clifton Road, 5th Floor - Atlanta, Georgia 30322
Tel: 404.712.0720 - Fax: 404.727.1358 - Email: irb@emory.edu - Web: <http://www.irb.emory.edu/>
An equal opportunity, affirmative action university